CHCWM – Cancer & Hematology Centers of West Michigan

GCT1046-01 (Genmab)

GCT1046-01 (Genmab)

 Description:   First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Mechanism of Action: bispecific antibody targeting PD-L1 and 4-1BB

Target Patient Population: Currently in Expansion with the following target populations:  NSCLC (PD-1/L1 pre-treated or naïve)

Study Design:  Study drug is given IV every 21 days.